ALLEVIATE

CANNABICS™ SR

Drug candidate for palliative treatment of Cancer related Anorexia-Cachexia Syndrome (CACS):

CANCER RELATED
ANOREXIA-CACHEXIA
SYNDROME (CACS):

CACS affects ~70-80% of patients in the advanced stages

Symptoms:

  • progressive weight loss & loss of appetite,
  • skeletal muscle wasting & reduced adipose tissue,
  • involuntary loss of more than 10% of the original weight

CACS adversely affects a patient’s quality of life,
and negatively predicts treatment outcome

CANCER RELATED<br>ANOREXIA-CACHEXIA<br>SYNDROME (CACS):
CANNABICS™ SR<br> FOR TREATMENT OF CACS

CANNABICS™ SR
FOR TREATMENT OF CACS

Drug candidate for palliative treatment of Cancer related Anorexia-Cachexia
Syndrome (CACS)

Proprietary formulation
*patent pending

Extended release oral capsule

Clinically tested for the treatment of CACS:

  • therapeutic effect of 8-10 hrs.
  • low dosage of psychoactive ingredient
  • no significant side effects

Peer-reviewed publication

CLINICAL STUDY (Pilot Study)

Tested doses:
5mgX1 or 5mgX2 capsules daily

Study Conclusions:

  • A weight increase of ≥10% in 17.6% of patients
  • No significant side effects
  • The results justify a larger study with dosage-controlled
    cannabis capsules in CACS
CLINICAL STUDY  (Pilot Study)